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It is well known that dopamine (DA) is critical for reward, but the precise role of
DA in reward remains uncertain. The aim of this study was to determine what
percentage of dopaminergic neurons in the primate brain is required for the expression
of conditioned reward by measuring the performance of DA-deficient rhesus monkeys
in a morphine-induced conditioned place preference (CPP) paradigm. Animals with mild
Parkinsonian symptoms successfully developed and retained a morphine preference that
was equivalent to control monkeys. However, these monkeys could not maintain the
preference as well as controls when they retained severe Parkinsonian symptoms. On the
other hand, monkeys initially in a severe Parkinsonian state developed a preference for
morphine, but this preference was weaker than that of the controls. Histological results
showed that the loss of dopaminergic neurons in monkeys that had severe Parkinsonian
symptoms was about 80% in comparison to the control monkeys. All these data suggest
that a severely impaired DA system alters rewarding-seeking behavior in non-human
primates.
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INTRODUCTION
Research, using diverse methods, has converged on the point that the dopamine (DA) system is
fundamentally important to reward related behaviors (Berridge and Robinson, 1998; Hyman, 2005;
Palmiter, 2008). It has been well established that drugs producing rewarding effects are dependent
on their ability to elevate extracellular DA levels in the mesolimbic DA system (Koob and Volkow,
2010). Morphine, for example, inhibits γ-amino-butyric acid (GABA) neurons in the ventral
tegmental area (VTA) through the binding of µ-opioid receptors, which results in the activation
of mesolimbic dopaminergic neurons (Nestler, 1992; Jalabert et al., 2011). In fact, animals that
self-administer morphine directly into the VTA have been found to display a place preference
(Altarifi and Negus, 2011), whereas administration of DA antagonists that block mesolimbic DA
transmission inhibits drug reward (Manzanedo et al., 2001).
Despite this ample evidence pointing to an essential role for DA in mediating reward
related behaviors (Spanagel and Weiss, 1999; Flagel et al., 2011), the amount of dopaminergic
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neurons that are needed in reward in mammalian brains
remains uncertain. To investigate this important question, the
performance of rhesus monkeys in conditioned place preference
(CPP) tasks was used as a marker of reward behavior in
this study. CPP has commonly been employed in drug-reward
experiments in which animals repeatedly receive a drug in
distinct chambers of a conditioning room and are subsequently
tested for their preference for each chamber (Tzschentke, 2007).
Rhesus monkeys were used here because these primates are
close relatives of humans and have the ability to exhibit a long-
lasting morphine-induced CPP, as demonstrated previously in
our laboratory (Wang et al., 2012). These characteristics of the
rhesus monkey make it an excellent model system to study
whether monkeys can establish and retain a morphine CPP while
burdened with impaired DA systems. Inducing different levels of
DA neuron loss will establish how much dopaminergic neuron
loss is needed for significant differences between DA-deficient
and control monkeys.
Dopaminergic neuron loss in the monkey brain was induced
in this study by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) toxicity. MPTP is a neurotoxin that causes the selective
death of dopaminergic neurons and as a result, a decrease
in the level of DA through the inhibition of mitochondrial
energy metabolism (Morfini et al., 2007). Humans and monkeys
receiving MPTP produce the entire triad of Parkinsonian
symptoms: bradykinesia, tremor and rigidity (Mounayar et al.,
2007). Monkeys in this study were assigned into different
groups to develop mild or severe Parkinsonian symptoms
by receiving two different MPTP intoxication protocols. The
monkeys’ Parkinsonian symptoms were graded to estimate the
degrees of impairment to the DA systems in the brain. Then
they were tested for morphine CPP. The preference scores
among the groups were compared to find out whether different
levels of DA system damage lead to different levels of drug
preference and to elucidate the precise role of DA in morphine
reward.
MATERIALS AND METHODS
Animals and Surgery
This study was carried out in strict accordance with the
guidelines for the National Care and Use of Animals (P.R. China)
as approved by the Institutional Animal Care andUse Committee
(IACUC) of the Kunming Institute of Zoology (approval ID
SWYX-2010012). All efforts were made to minimize suffering.
Twelve male rhesus monkeys (macaca mulatta; 8–10 years
old, 8–11 kg) from the breeding colonies of the Kunming
Institute of Zoology were used in this study. These animals
were housed under controlled conditions of humidity (60%),
temperature (20◦C ± 2◦C) and light (12:12 h light:dark cycle).
All the animals were fed with commercial monkey biscuits twice
a day and water was available ad libitum. Fruits and vegetables
were given to the monkeys once daily.
In accordance with the MPTP intoxication protocols,
the 12 monkeys were divided into three groups: group I
(n = 5, intramuscular MPTP administration), group II (n = 3,
intracerebroventricular MPTP administration) and the control
group (n = 4, intramuscular saline administration). Because
previous study has demonstrated that intracerebroventricular
saline administration does not impair monkey’s motor ability (Li
et al., 2015), no control group receiving intracerebroventricular
saline administration had been designed in this study. Before
any MPTP administration, each monkey in group II received
surgery and had a silicon tube inserted into the lateral cerebral
ventricle. This tube acted as a guide for intracerebroventricular
MPTP administration.
Before surgery, the monkeys in group II underwent a fast
for 12 h. For surgery, each monkey was initially anesthetized
with ketamine (10 mg/kg, i.m.) and then maintained on sodium
pentobarbital (15 mg/kg, i.m.) anesthesia for the duration of the
surgery. Atropine (0.1 ml/kg, i.m.) was administered with the
initial ketamine injection to decrease respiratory secretions. The
coordinates of the silicon tube locations were obtained through
an MRI-based localization method developed by our laboratory
(Jing et al., 2010). The operation was carried out according
to the MRI coordinates using a stereotaxic apparatus (SN-2N,
Narishige, Japan). Then the silicon tube was fixed onto the top of
the skull with dental cement. The following experiments (MPTP
treatments and CPP tests) were performed only after the animals
had fully recovered, which usually took 7–10 days.
Experimental Schedule
After the group II monkeys had fully recovered from the
surgeries, animals in group I and group II were subjected
to MPTP (Sigma, St Louis, MO, USA) treatments. The five
monkeys in group I initially underwent a progressive intoxication
(0.25 mg/kg, i.m., injections spaced by 2–3 days; Figure 1).
Injections were repeated until mild Parkinsonian symptoms had
been developed (see ‘‘Behavioral Analysis’’ Section described
later). After the progressive intoxication, the group I monkeys
were subjected to the CPP procedure (described below) and
were tested twice in 12 months (Figure 1). Then these animals
received an acute intoxication of MPTP (0.45 mg/kg, i.m., 6 or 7
daily injections) to damage any residual dopaminergic neurons
and produce a strong symptomatic state (Figure 1). After the
acute intoxication, these monkeys were retested for CPP a third
time.
The three monkeys in group II received 10–12 daily
intracerebroventricular injections (5 mg per kg of brain weight
(Sullivan et al., 1997) to develop strong and stable symptoms
(Figure 1). After the acute MPTP intoxication, the group II
monkeys underwent the CPP procedure only once (Figure 1).
The control group was administered saline of the same
volume/mass as the MPTP-administered monkeys in group I.
These animals were subjected to the CPP experiment on the day
group I monkeys started the CPP experiment, and were tested
twice in 12 months (Figure 1).
Behavioral Analysis—Parkinsonian
Symptoms
Infrared cameras were used to record the animals’ behavior for
the analysis of Parkinsonism. The severity of Parkinsonism was
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FIGURE 1 | Timelines and protocols of methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication and conditioned place preference (CPP)
training. Group I monkeys initially received progressive MPTP injections for 3 to 4 months (0.25 mg/kg, i.m., injections spaced by 2–3 days) until they developed
mild PD symptoms. After the progressive intoxication, the group I monkeys were subjected to the CPP procedure. The group I monkeys were tested two times in 12
months. Then these animals received acute injections of MPTP (0.45 mg/kg, i.m., 6–7 daily injections) and developed strong PD symptoms. Then the third CPP test
was carried out. The group II monkeys received an acute MPTP intoxication protocol (intracerebroventricular, 5 mg per kg of brain weight, 10–12 daily injections) and
developed strong PD symptoms. These animals were tested only once to examine whether they had established a morphine CPP with severe Parkinsonian
symptoms. The control group performed the CPP test twice: the first one coincided with CPP training and testing of the group I monkeys; the second test was
performed 12 months after the first one.
evaluated using the rating scale proposed by Kurlan (Smith et al.,
1993). The scale includes seven items rated between 0 and 2 or
4, with a total score of 20. It takes into account classical motor
symptoms (tremor, bradykinesia, posture and arm posture) as
well as other activities (arm movements, balance and defensive
reaction).
Each monkey was recorded daily for 1 h (10–11 am) to
evaluate the development of the Parkinsonian symptoms. Each
1 h recording was split equally into four parts (15 min each)
and the scores of the four parts were averaged to obtain
the daily total score. In this study, group I monkeys first
developed mild Parkinsonian symptoms (scores were between
5 and 7), and then the symptoms were aggravated to establish
severely impaired DA systems (scores exceeding 10) by acutely
administering more MPTP after a 12-month recovery period.
Group II monkeys developed strong and stable symptoms (scores
exceeding 10).
Behavioral Analysis—CPP
Prior to all CPP experiments, the monkeys received a primate
collar under ketamine hydrochloride (5 mg/kg, i.m.) anesthesia
at least 1 week before the start of the CPP experiment.
This enabled the experimenter to take the animals to the
conditioning room. The CPP experiment was conducted using
the same apparatus previously described in our laboratory
(Wang et al., 2012). Briefly, the conditioning space was
composed of three square rooms connected in a row. The
sizes of the two side rooms were 190 × 190 × 265 cm
(l × w × h), respectively, and the middle room (start
room) was 210 × 210 × 265 cm. Specifically colored pieces
of paper were glued on the walls of the three rooms to
provide different visual cues to the animals. Cameras were
installed on the top of the rooms to record the monkeys’
behavior.
The CPP training procedure included 3 days of habituation,
12 days of conditioning and 3 days of CPP testing. In the adaptive
phase, the 12 monkeys were individually guided into the start
roomwhere they could freely move in the three rooms for 50 min
on three continuous days and thus they became completely
familiar with the three rooms. After the 3 days of habituation,
each animal had a preferred room that served as its saline-paired
room during the conditioning, while the other side room that the
monkey did not prefer served as its morphine-paired room. In
the conditioning days, animals received a morphine (or saline)
injection in their own cages and were subsequently taken to the
morphine-paired room (or the saline-paired room) and stayed
for 50 min. The dose of morphine started at 1.5 mg/kg (i.m.) and
increased to 3 and 4.5 mg/kg on the two following alternate days.
The highest dose of 4.5 mg/kg was then maintained for the last
3 days (Wang et al., 2012). Saline was given at the same volume as
morphine on the 6 days that alternated with the morphine days.
After the days of habituation and conditioning, the animals
were tested for CPP. Each testing lasted for 30 min on three
continuous days. Group I was tested three times: 24 h after the
CPP conditioning was completed, when themonkeysmaintained
mild Parkinsonian symptoms (0-month CPP), 12 months later
when the monkeys had recovered from the progressive MPTP
treatments (12-month CPP), and 12.25 months later when the
monkeys had received additional acute MPTP injections and
were in a strong PD symptomatic state (12.25-month CPP).
Group II were tested only one time (0-month CPP). Control
group was tested at time point 0 (0-month CPP) and 12 months
later (12-month CPP).
The morphine hydrochloride (C17H19NO3•HCl•3H2O) was
purchased from Sheng Yang, 1st Medical Company (Sheng Yang,
China).
All 12 monkeys were sacrificed at the end of the CPP
experiments for histological analysis.
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Histological Analysis
After the CPP experiments, all animals received deep anesthesia
with an overdose of sodium pentobarbital (40 mg/kg, i.m.)
and were then transcardially perfused with saline followed by a
fixative containing 4% paraformaldehyde in a phosphate buffer
(0.1 M, pH 7.4). Brains were sliced in 50 µm-thick coronal
sections using a freezing microtome (Leica CM1850, Germany).
Ten regularly spaced sections covering the anteroposterior extent
of the substantia nigra (SN) and the VTA, from each of the
12 monkeys, were processed for light microscopic analysis of
tyrosine hydroxylase (TH) immunolabeling.
Immunoreactivity for TH was localized using the protocol
of Mazloom and Smith (2006). Briefly, sections were stained
with primary rabbit polyclonal TH antibodies (1/1000 dilution;
Chemicon Intl, Temecula, CA, USA; catalog #AB152#), followed
by a secondary biotinylated goat anti-rabbit immunoglobulin
G (1/200 dilution; Maxim Co. Ltd., China). Visualization
was achieved using an avidin-biotin-peroxidase complex (ABC
standard kit; 1:200 dilution in phosphate-buffered saline;Maxim)
and 3,3′-diaminobenzidine tetrahydrochloride (5%; Maxim).
Sections were examined with an Olympus CX41 microscope
(Tokyo, Japan), and images were acquired with a CCD
camera (Sony DP25, Tokyo, Japan) controlled by the Olympus
cellSens software. TH-positive cells were counted in the ten
regularly spaced sections with an image analysis system (Image-
Pro Plus, Media Cybernetics, Shanghai, China). The sections
were matched anatomically in each of the animals, verifying
that the cross sections of the midbrain were similar in the
controls and PD monkeys. The percentages of neuronal loss
in the SN and VTA in the MPTP-treated monkeys were
evaluated by comparison with the control values of intact
monkeys.
Data Analysis
The time spent in the rooms during each CPP testing was
recorded for analyzing the animals’ preference formorphine. The
preference score was expressed by time spent inmorphine-paired
roomminus time spent in saline-paired room (Smith et al., 2012).
All 3 days of each testing were scored and then tested to find out
whether the scores decay over the 3 days. One-way analysis of
variance followed by Tukey’s test as post hoc analysis was used
and no decay was found (Figure 2). Therefore, the scores of the
3 days were averaged to obtain the preference score. The walking
distance was recorded as an index of locomotor activity (Wang
et al., 2012).
The differences in the preference scores before and after
CPP conditioning were assessed for each group using a paired
t-test (Tp) or one-way analysis of variance followed by Tukey’s
test as post hoc analysis. The preference scores among the
three groups before and after CPP conditioning were analyzed
using an independent t-test (Ti) or one-way analysis of variance
followed by Tukey’s test as post hoc analysis. The walking distance
among the three rooms in each group and the total walking
distance among the three groups were analyzed using one-
way analysis of variance followed by Tukey’s test as post hoc
analysis.
FIGURE 2 | The preference scores in the 3 days of each CPP testing. No decay was found during each testing. (A) The preference scores of the three groups
before CPP conditioning (F(2,9) = 0.012, P = 0.989 for control group, F(2,12) = 0.031, P = 0.970 for group I, F(2,6) = 0.039, P = 0.962 for group II). (B) The preference
scores of the three groups during the 0 month-CPP phase (F(2,9) = 0.561, P = 0.590 for control group, F(2,12) = 0.158, P = 0.855 for group I, F(2,6) = 0.473,
P = 0.645 for group II). (C) The preference scores of group I and control group during the 12 month-CPP phase (F(2,9) = 0.068, P = 0.935 for control group,
F(2,12) = 0.283, P = 0.759 for group I). (D) The preference scores of group I during the 12.25 month-CPP phase (F(2,12) = 0.118, P = 0.890).
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Optical quantification of neurons in the SN and VTA were
analyzed using the Mann-Whitney U test to compare group I,
group II and the control group.
Differences were considered statistically significant at
p < 0.05. All data were presented as the mean ± standard error
of mean.
RESULTS
Parkinsonism Aspects
The monkeys in group I initially received 12–15 (mean
13.2 ± 1.1) weeks of progressive MPTP injections for a
cumulative dose of 6–7.5 mg/kg (mean 6.6 ± 0.6 mg/kg).
These animals developed mild symptoms (weak tremor or
bradykinesia; Kurlan scores were between 5 and 7). All of
these animals experienced a total recovery after stopping MPTP
treatment (Figure 3A). After receiving additional acute MPTP
intoxication (6–7 days of individual injections), these animals
rapidly developed severe symptoms with Kurlan scores larger
than 10 (Figure 3B). Group II monkeys displayed similar
Parkinsonian symptoms after their acute MPTP intoxication
(10–12 days of individual injections, a cumulative dose of
5–6 mg; Figure 3B). Monkeys (in both group I and group II)
that developed severe symptoms exhibited little recovery after the
cessation of the acute MPTP intoxication (Figure 3B).
CPP Aspects
Pre-CPP
After moving about the three rooms, all 12 of the monkeys
preferred to stay a longer time in one of the three rooms in
the habituation stage before morphine administration (Table 1).
Furthermore, the preference scores were not statistically different
among the three groups (F(2,9) = 3.192, P = 0.09). This provided
a platform for the later post-CPP (0-month CPP, 12-month CPP,
12.25-month CPP) comparisons among the three groups.
0-Month CPP
24 h after the morphine conditioning (0-month CPP), morphine
treatment produced a significant switch in the time spent in the
morphine-paired room (Tp = −18.220, P = 0.000 for the control
group; Tp =−8.444, P = 0.001 for group I; Tp =−7.655, P = 0.019
for group II).
During this phase, the monkeys also walked a longer distance
in the morphine-paired room than in the other two rooms
(F(2,9) = 18.106, P = 0.001 for control group; F(2,12) = 5.761,
P = 0.018 for group I; Figure 4A). In the control group, post
hoc analysis (Tukey’s test) showed that the walking distance in
the morphine-paired room was higher than in the saline-paired
room (T = 5.585, P = 0.001; Figure 4A). In group I monkeys, post
hoc analysis (Tukey’s test) showed that the walking distance in
the morphine-paired room was higher than in the saline-paired
room (T = 3.019, P = 0.027; Figure 4A).
The results of the comparisons among the three groups
showed that there were significant differences among the three
groups (F(2,9) = 102.770, P = 0.000; Figure 5A). Post hoc analysis
(Tukey’s test) showed that the establishment of the morphine
FIGURE 3 | Evolution of motor scores in group I and II monkeys during
MPTP intoxication periods. (A) The appearance and disappearance of
symptoms in group I monkeys during and after the progressive MPTP
intoxication. The group I monkeys received progressive intoxication and
developed mild Parkinsonian symptoms (Kurlan scores between 5 and 7).
Timelines are aligned such that day 0 corresponds to the day on which the
maximal motor Kurlan score was obtained from an individual animal and
MPTP injections were stopped. (B) The reappearance of symptoms in group I
monkeys and the appearance of symptoms in group II monkeys during and
after acute MPTP intoxications. Group I and II, which received acute MPTP
intoxications, displayed severe Parkinsonian symptoms (Kurlan scores
exceeding 10) and exhibited little recovery until the time of being sacrificed for
histological examinations. Day 0 corresponds to the day on which the
injections were stopped. The animals in group I were sacrificed on day 4 or
day 5 (the day after their third CPP test). Group I monkeys are represented
with continuous lines and group II with dotted lines.
CPP in the group IImonkeys was not as strong as in the other two
groups (T = 13.122, P = 0.000 for controls; T = 12.472, P = 0.000
for group I, compared with group II). Conversely, the group
I monkeys showed a similar preference to the control group
(T = 1.362, P = 0.399; Figure 5A). The total walking distance were
not statistically different among the three groups (F(2,9) = 0.120,
P = 0.889; Figure 5B).
12-Month CPP
Twelve months after the original morphine CPP conditioning,
the monkeys in group I and the control group still prefer the
morphine-paired room (one-way ANOVA between pre-CPP,
0-month CPP, and 12-month CPP, F(2,9) = 143.408, P = 0.000
for the control group, F(2,12) = 59.620, P = 0.000 for group I).
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TABLE 1 | The time spent in the three rooms in all monkeys during the
pre-CPP phase.
Room 1 Room 2 Room 3
Control Group
Monkey 1 374.3 824.3 601.3
Monkey 2 192.3 847.3 760.3
Monkey 3 984.0 696.7 119.3
Monkey 4 885.0 470.7 444.3
Group I
Monkey 5 422.7 2.0 1375.3
Monkey 6 1648.0 142.0 10.0
Monkey 7 480.7 532.0 787.3
Monkey 8 175.7 24.0 1600.3
Monkey 9 137.7 998.0 664.3
Group II
Monkey 10 374.7 1264.7 160.7
Monkey 11 251.0 1464.3 83.7
Monkey 12 789.3 558.0 452.7
Room 1 and room 3 were the two lateral rooms which served as drug-paired room
or saline-paired room during the conditioning phase. The middle room (room 2)
serves as the start room. Each score (seconds) in the table was obtained from
averaging the three scores of the habituation days.
In the control group, post hoc analysis (Tukey’s test) showed
that the preference score in the 12-month phase was higher
than the score in the pre-CPP phase (T = 9.652, P = 0.000)
and was lower than the score in the 0-month phase (T = 7.226,
P = 0.000; Figure 5A). In group I monkeys, post hoc analysis
(Tukey’s test) showed that the preference score in the 12-month
FIGURE 4 | The walking distance of all monkeys measured within a
30-min test. (A) The walking distance in the three rooms 24 h after CPP
(0 month-CPP). (B) The walking distance in the three rooms 12 months after
CPP (12 month-CPP). (C) The walking distance in the three rooms 12.25
months after CPP (12.25 month-CPP). ∗p < 0.05, ∗∗p < 0.01. Data are
presented as mean ± SEM.
FIGURE 5 | The preference scores and the total walking distance of all
monkeys measured within a 30-min test. (A) The preference scores
of time spent in the morphine-paired room after CPP conditioning.
Comparisons within each group revealed that all three groups showed
significant switch in their time spent in the morphine-paired room after
conditioning. Comparisons among groups showed that the preference scores
in monkeys with severe Parkinsonian symptoms (group I in the 12.25-month
phase and group II in the 0-month phase) were significantly lower than the
control group. (B) The total walking distance of the three rooms. Comparisons
within groups showed no significant difference among different testing phases.
Comparison among groups showed only the walking distance of group I at
12.25-month CPP testing phase was significantly less than the control group
at 12-month CPP testing timepoint. ∗∗p < 0.01: inter-group comparisons.
#p < 0.05, ##p < 0.01: comparisons among groups. Data are presented as
mean ± SEM.
phase was higher than the score in the pre-CPP phase (T = 8.865,
P = 0.000) and was not statistically different from the score in the
0-month phase (T = 1.089, P = 0.538; Figure 5A). On the other
hand, post hoc analysis showed that no difference of walking
distance was found between morphine-paired room and saline-
paired room (T = 1.932, P = 0.185 for control group, T = 1.504,
P = 0.324 for group I; Figure 4B).
When comparing between group I and control group,
monkeys in group I showed even higher preference score than
control group (Ti = −2.589, P = 0.041; Figure 5A). The total
walking distance were not statistically different between the two
groups (Ti = 0.352, P = 0.735; Figure 5B).
12.25-Month CPP
The 12.25-month test was carried out only 6–7 days after the
12-month test in group I. Because the performance did not decay
over the 3 days of each testing, we assumed the performance
of control group did not decay 6–7 days after the 12-month
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FIGURE 6 | Tyrosine hydroxylase (TH) labeling in the mesencephalon of the rhesus monkeys. (A) Depiction of areas used to define the SN and ventral
tegmental area (VTA) and examples of the distribution of TH immunostaining in the mesencephalon from the control group, group I and group II, respectively. Scale
bar: 1 mm. (B) Density of TH-positive neurons that remained in the mesencephalon of three groups. ∗p < 0.05. Data are presented as mean ± SEM.
test. Therefore, the control group did not go through the
12.25-month CPP test. The preference score of group I during
the 12.25-month CPP test (after the acute MPTP intoxication)
was compared with the score during the 12-month test in control
group. Significantly decrease was found in group I monkeys
(Ti = −3.383, P = 0.012; Figure 5A). The total walking distance
of group I was also less than the control group (Ti = 3.094,
P = 0.017; Figure 5B). On the other hand, the walking distance in
the morphine-paried room was not significantly different from
the other two rooms (F = 2.127, P = 0.162; Figure 4C).
Immunohistochemical Aspects
An immunohistochemical analysis of TH was performed on all
groups to confirm that the loss of dopaminergic neurons in the
group I and II monkeys that had severe Parkinsonian symptoms
at the time of sacrifice was similar to or larger than the 70% loss
of dopaminergic neurons witnessed in previous studies (Burns
et al., 1983; Elsworth et al., 2000; Mounayar et al., 2007). The
monkeys in group I and group II both exhibited an extensive loss
of TH-positive neurons in comparison to the control monkeys
evaluated in this study (group I: 79%, P = 0.011; group II: 80%,
P = 0.019; Figure 6). In the VTA, the loss of TH-positive neurons
in group I and group II was 50 and 47%, respectively. The SN
was more sensitive with a loss of 85% in group I and a loss of 84%
in group II. In addition, no statistical difference in cell loss was
found between the group I and group II monkeys (P = 0.881 for
SN and VTA; P = 0.655 for total).
DISCUSSION
Reward has been associated with dopaminergic function. The
results of this study, the first to be carried out on rhesus monkeys,
found that severe dopaminergic neurons loss impaired CPP for
morphine. This study confirmed previous studies carried out on
rodents that had suggested that DA had the ability to facilitate
reward related behaviors (Berridge and Robinson, 1998; Cannon
and Palmiter, 2003; Hnasko et al., 2005). Moreover, this study
also revealed that this ability of DA had not been impaired in
monkeys existingmild Parkinsonian symptoms as thesemonkeys
with can normally establish and retain a morphine preference.
The previous rodent studies had not been able to make this point
as the rodents were in a severe state and had less than 1% of
normal brain DA concentrations when the previous preference
experiments were performed (Berridge and Robinson, 1998;
Hnasko et al., 2005).
According to previous studies, reward contains three
components: liking, learning and wanting (Berridge and
Robinson, 1998; Berridge, 2007). The association of the sensory
pleasure (liking) of morphine with the environment (dependent
on learning) is formed during the CPP conditioning session
(CPP acquisition), and then is revealed during the testing
phase (Hnasko et al., 2005). Wanting is a motivation response
triggered by and assigned to a reward-related stimulus and is
evident during the testing phase (CPP expression). Without
motivation, the animal may simply sit still and not manifest a
preference (Berridge, 2007). In this study, group I monkeys with
mild Parkinsonian symptoms displayed a strong preference for
the morphine-paired room which was similar to the controls.
This result suggested that existing mild Parkinsonian symptoms
would not affect any component of reward.
Furthermore, when monkeys exhibited severe Parkinsonian
symptoms, they spent less time in the morphine-paired room
than did the controls (Caution must be exercised in interpreting
the results from Group I at the 12.25 month timepoint as we
did not perform a CPP test at the 12.25 month timepoint in the
control group, and as such the reduced CPP score could result
from the repeated testing). Thus, severe loss of dopaminergic
neurons provided profound constraints on CPP performance.
Because these monkeys still had the motor ability and readily
explored the CPP rooms, motor deficits failed to explain the
less time monkeys spent in the morphine-paired room after the
development of severe Parkinsonian symptoms. However, the
results from the group I monkeys suggested that this abnormal
performance may contribute to the deficit in motivation for
morphine. In the group I monkeys, the preference score was
initially similar to the controls (0-month and 12-month CPP
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tests), which meant that they had acquired CPP normally.
Therefore, the significantly decreased score at the 12.25 month
timepoint provided evidence that severe DA depletion reduced
animals’ wanting for morphine.
In this study, only group II monkeys acquired CPP with
severe dopaminergic neuron loss. However, the significantly
lower score in group II (compared to control group) during the 0-
month testing phase failed to reveal whether severe DA depletion
impaired the acquisition of CPP, as the CPP testing phase
included not only the acquisition of CPP but also wanting, and
group II monkeys’ wanting for morphine was possibly impaired
(inferred from the evidence of the 12.25-month test in group
I). Combining with the result of the group I (0-month testing
phase), our data only proved that mild Parkinsonian symptoms
would not affect monkey’s acquisition of CPP.
As demonstrated in this DA-deficient primate model, DA
has the ability to facilitate the manifestation of place preference.
Furthermore, this ability only begins to become impaired when
the degree of Parkinsonian symptoms exceeds a mild state. This
novel finding, obtained from monkeys, provides a good basis
for further investigations into the neural pathways and brain
structures (e.g., the medial prefrontal cortex) involved in reward
development.
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